Cargando…

Efficacy and Safety of Dulaglutide Monotherapy Compared to Glimepiride in Oral Antihyperglycemic Medication-Naïve Chinese patients with Type 2 Diabetes: A Post Hoc Analysis of AWARD-CHN1

INTRODUCTION: Glucagon-like peptide (GLP)-1 receptor agonists are glucose-lowering agents associated with weight loss, cardiovascular benefits, and low hypoglycemic risk and are recommended by recent guidelines as first-line therapy for some patients with type 2 diabetes (T2D). This post hoc analysi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Yi Ming, Zhang, Li Hui, Li, Xue Jun, Zhang, Bin, Hou, Jia Ning, Tong, Nan Wei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7192982/ https://www.ncbi.nlm.nih.gov/pubmed/32219675 http://dx.doi.org/10.1007/s13300-020-00799-w

Ejemplares similares

Efficacy and Safety of Once-Weekly Dulaglutide in Elderly Chinese Patients with Type 2 Diabetes: A Post Hoc Analysis of AWARD-CHN Studies
por: Kuang, Jian, et al.
Publicado: (2020)

Efficacy of Dulaglutide in Chinese Patients with Type 2 Diabetes and Different Glycemic Patterns: a Post-hoc Analysis of the Phase 3 AWARD-CHN2 Trial
por: Li, Qifu, et al.
Publicado: (2021)

Efficacy and Safety of Dulaglutide Versus Insulin Glargine in Chinese T2DM Patients: A Subgroup Analysis of a Randomized Trial (AWARD-CHN2)
por: Li, Yan, et al.
Publicado: (2019)

Efficacy and safety of dulaglutide monotherapy compared with glimepiride in Chinese patients with type 2 diabetes: Post‐hoc analyses of a randomized, double‐blind, phase III study
por: Shi, Li Xin, et al.
Publicado: (2019)

Study Design and Baseline Characteristics of Patients with T2DM in the Post-marketing Safety Study of Dulaglutide in China (TRUST-CHN)
por: Guo, Lixin, et al.
Publicado: (2022)

A 24‐week study to evaluate the efficacy and safety of once‐weekly dulaglutide added on to glimepiride in type 2 diabetes (AWARD‐8)
por: Dungan, K. M., et al.
Publicado: (2016)

Efficacy and safety of dulaglutide monotherapy compared with glimepiride in East‐Asian patients with type 2 diabetes in a multicentre, double‐blind, randomized, parallel‐arm, active comparator, phase III trial
por: Chen, Yu Hong, et al.
Publicado: (2018)

Efficacy of Dulaglutide Expanded Doses by Baseline A1C Categories: Post Hoc Analysis of AWARD-11
por: Frias, Juan Pablo, et al.
Publicado: (2021)

Comparison of the Efficacy of Glimepiride, Metformin, and Rosiglitazone Monotherapy in Korean Drug-Naïve Type 2 Diabetic Patients: The Practical Evidence of Antidiabetic Monotherapy Study
por: Yoon, Kun Ho, et al.
Publicado: (2011)

Factors associated with adherence to oral antihyperglycemic monotherapy in patients with type 2 diabetes
por: Tunceli, Kaan, et al.
Publicado: (2015)

Complete Genome Characterization of Chinese Porcine Deltacoronavirus Strain CHN/Tianjin/2016
por: Zhao, Feng, et al.
Publicado: (2017)

Prophage-encoded gene VpaChn25_0734 amplifies ecological persistence of Vibrio parahaemolyticus CHN25
por: Xu, Yingwei, et al.
Publicado: (2022)

Glycaemic efficacy of an expanded dose range of dulaglutide according to baseline glycated haemoglobin (HbA1c) subgroup: Post hoc analysis of AWARD‐11
por: Frias, Juan P., et al.
Publicado: (2021)

Dulaglutide and Insulin: How Can the AWARD Studies Help Guide Clinical Practice?
por: MacIsaac, Richard J.
Publicado: (2020)

Isolation, genomic characterization, and pathogenicity of a Chinese porcine deltacoronavirus strain CHN-HN-2014
por: Dong, Nan, et al.
Publicado: (2016)

Efficacy and Safety of Dulaglutide by Baseline HbA1c in Chinese Patients with Type 2 Diabetes: A Post Hoc Analysis
por: Yu, Miao, et al.
Publicado: (2020)

Efficacy and Safety of Dulaglutide in Older Patients: A post hoc Analysis of the REWIND trial
por: Riddle, Matthew C, et al.
Publicado: (2021)

Evaluation of Characteristics of Gastrointestinal Adverse Events with Once-Weekly Dulaglutide Treatment in Chinese Patients with Type 2 Diabetes: A Post Hoc Pooled Analysis of Two Randomized Trials
por: Guo, Lixin, et al.
Publicado: (2020)

Prophage-Related Gene VpaChn25_0724 Contributes to Cell Membrane Integrity and Growth of Vibrio parahaemolyticus CHN25
por: Yang, Lianzhi, et al.
Publicado: (2020)

Complete Genome Sequences of Two Porcine Deltacoronavirus Strains, CHN-GD16-03 and CHN-GD16-05, Isolated in Southern China, 2016
por: Mai, Kaijie, et al.
Publicado: (2018)

Gastrointestinal Tolerability of Once-Weekly Dulaglutide 3.0 mg and 4.5 mg: A Post Hoc Analysis of the Incidence and Prevalence of Nausea, Vomiting, and Diarrhea in AWARD-11
por: Van, Joanna, et al.
Publicado: (2021)

Efficacy and safety of dulaglutide 3.0 and 4.5 mg in patients aged younger than 65 and 65 years or older: Post hoc analysis of the AWARD‐11 trial
por: Frias, Juan P., et al.
Publicado: (2021)

Glimepiride monotherapy versus combination of glimepiride and linagliptin therapy in patients with HNF1A-diabetes: a protocol for a randomised, double-blinded, placebo-controlled trial
por: Sidelmann Christensen, Alexander, et al.
Publicado: (2018)

Effect of once weekly dulaglutide by baseline beta‐cell function in people with type 2 diabetes in the AWARD programme
por: Mathieu, Chantal, et al.
Publicado: (2018)

CPVL/CHN2 Genetic Variant Is Associated With Diabetic Retinopathy in Chinese Type 2 Diabetic Patients
por: Hu, Cheng, et al.
Publicado: (2011)

Comparative efficacy of glimepiride and metformin in monotherapy of type 2 diabetes mellitus: meta-analysis of randomized controlled trials
por: Zhu, Hongmei, et al.
Publicado: (2013)

Effect of once‐weekly dulaglutide versus insulin glargine in people with type 2 diabetes and different baseline glycaemic patterns: A post hoc analysis of the AWARD‐2 clinical trial
por: Giorgino, Francesco, et al.
Publicado: (2019)

A Randomized Study to Compare the Effects of Once-Weekly Dulaglutide Injection and Once-Daily Glimepiride on Glucose Fluctuation of Type 2 Diabetes Mellitus Patients: A 26-Week Follow-Up
por: Li, Huiqin, et al.
Publicado: (2019)

Efficacy and safety outcomes of dulaglutide by baseline HbA1c: A post hoc analysis of the REWIND trial
por: Franek, Edward, et al.
Publicado: (2022)

Achieving the composite end‐point of glycated hemoglobin <7.0% without weight gain or hypoglycemia with once‐weekly dulaglutide in Chinese patients with type 2 diabetes: A post‐hoc analysis
por: Xiao, Xinhua, et al.
Publicado: (2020)

Genomic characterization and pathogenicity of porcine deltacoronavirus strain CHN-HG-2017 from China
por: Zhang, Meng-Jia, et al.
Publicado: (2018)

Efficacy and Safety of Dulaglutide 3.0 mg and 4.5 mg Versus Dulaglutide 1.5 mg in Metformin-Treated Patients With Type 2 Diabetes in a Randomized Controlled Trial (AWARD-11)
por: Frias, Juan P., et al.
Publicado: (2021)

A post-hoc analysis of the comparative efficacy of canagliflozin and glimepiride in the attainment of type 2 diabetes-related quality measures
por: Patel, Charmi A., et al.
Publicado: (2016)

Bioinformatics-based analysis of the association between the A1-chimaerin (CHN1) gene and gastric cancer
por: Li, Jie-Pin, et al.
Publicado: (2021)

Efficacy of Dulaglutide as a First Injectable Option for Patients with Type 2 Diabetes: A Post-Hoc Pooled Analysis
por: Patel, Hiren, et al.
Publicado: (2019)

Impact of patient characteristics on efficacy and safety of once-weekly semaglutide versus dulaglutide: SUSTAIN 7 post hoc analyses
por: Pratley, Richard E, et al.
Publicado: (2020)

CHN2 Promoter Methylation Change May Be Associated With Methamphetamine Dependence
Publicado: (2017)

The Risk of Overall Mortality in Patients With Type 2 Diabetes Receiving Glipizide, Glyburide, or Glimepiride Monotherapy: A retrospective analysis
por: Pantalone, Kevin M., et al.
Publicado: (2010)

Identification of a novel CHN1 p.(Phe213Val) variant in a large Han Chinese family with congenital Duane retraction syndrome
por: Zhou, Tai-Cheng, et al.
Publicado: (2020)

Gliclazide monotherapy increases risks of all-cause mortality and has similar risk of acute myocardial infarction and stroke with glimepiride monotherapy in Korean type 2 diabetes mellitus
por: Cho, Eun-Hee, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_coocs9c8dtkd7nvjnl8po9bdc2